US Patent

US8968753 — Ceftolozane-tazobactam pharmaceutical compositions

Method of Use · Assigned to Calixa Therapeutics Inc · Expires 2034-03-14 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions that include ceftolozane lyophilized without tazobactam.

USPTO Abstract

Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1673`	—

Patent Metadata

Patent number: US8968753
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Calixa Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.